827318-97-8 | Danusertib

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$44.00	$31.00
5mg	95%	in stock	$80.00	$56.00
10mg	95%	in stock	$110.00	$77.00
25mg	95%	in stock	$169.00	$119.00
100mg	95%	in stock	$462.00	$323.00
250mg	95%	in stock	$1,027.00	$719.00

Description

• Catalog Number: AB72481
• Chemical Name: Danusertib
• CAS Number: 827318-97-8
• Molecular Formula: C26H30N6O3
• Molecular Weight: 474.5548
• MDL Number: MFCD12024692
• SMILES: CO[C@@H](C(=O)N1Cc2c(C1)[nH]nc2NC(=O)c1ccc(cc1)N1CCN(CC1)C)c1ccccc1

Computed Properties

• Complexity: 731
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 35
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 6
• XLogP3: 1.8

Literature

• Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance.

  Journal of molecular biology 20170217

• Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells.

  PloS one 20140101

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML.

  Nature chemical biology 20121101

• Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120901

• Danusertib, an aurora kinase inhibitor.

  Expert opinion on investigational drugs 20120301

• Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells.

  Gene 20120225

• In vitro drug metabolism by C-terminally truncated human flavin-containing monooxygenase 3.

  Biochemical pharmacology 20120215

• Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.

  Clinical Medicine Insights. Oncology 20120101

• Tyrosine kinase inhibitors in hematological malignancies.

  Postepy higieny i medycyny doswiadczalnej (Online) 20111205

• Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.

  Investigational new drugs 20111001

• An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B.

  Molecular cancer therapeutics 20111001

• New drugs for chronic myelogenous leukemia.

  Current hematologic malignancy reports 20110601

• The molecular mechanism studies of chirality effect of PHA-739358 on Aurora kinase A by molecular dynamics simulation and free energy calculations.

  Journal of computer-aided molecular design 20110201

• Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.

  PloS one 20110101

• Dynamics of resistance development to imatinib under increasing selection pressure: a combination of mathematical models and in vitro data.

  PloS one 20110101

• Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.

  Cancer research 20101201

• A type-II kinase inhibitor capable of inhibiting the T315I 'gatekeeper' mutant of Bcr-Abl.

  Journal of medicinal chemistry 20100812

• Identification of Myb-binding protein 1A (MYBBP1A) as a novel substrate for aurora B kinase.

  The Journal of biological chemistry 20100416

• Aurora kinase inhibitors as anti-cancer therapy.

  Anti-cancer drugs 20100401

• Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20100101

• Optimizing combination therapies with existing and future CML drugs.

  PloS one 20100101

• A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091101

• Overcoming resistance in chronic myelogenous leukemia.

  Leukemia & lymphoma 20091101

• Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091020

• Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.

  Neoplasia (New York, N.Y.) 20090901

• Discovery and development of aurora kinase inhibitors as anticancer agents.

  Journal of medicinal chemistry 20090514

• Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

  Blood 20080415

• Aurora kinase A inhibitors: identification, SAR exploration and molecular modeling of 6,7-dihydro-4H-pyrazolo-[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-dione scaffold.

  Bioorganic & medicinal chemistry letters 20080301

• Inhibitors of ABL and the ABL-T315I mutation.

  Current topics in medicinal chemistry 20080101

• PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.

  Molecular cancer therapeutics 20071201

• Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.

  Cancer research 20070901

• 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.

  Journal of medicinal chemistry 20061130